Quick Answer
The US FDA is moving to permanently ban bulk compounding of semaglutide and tirzepatide after 775+ adverse event reports. Indian patients should avoid unregulated GLP-1 products sold online.
Free Consultation
Have questions about GLP-1 Therapy?
Enter your phone number — a specialist calls you back in 30 minutes. Free, no commitment.
🔒 Confidential · No spam · 10,000+ patients helped
If you have seen cheap semaglutide or tirzepatide being sold through websites, social media sellers, or imported peptide vials, the latest move by the US drug regulator is a warning worth reading. The US Food and Drug Administration has formally proposed to exclude semaglutide, tirzepatide, and liraglutide from its 503B bulks list — effectively moving to permanently shut down large-scale pharmacy compounding of these GLP-1 drugs. The FDA found no clinical need for compounded copies now that approved versions are widely available, and the decision follows more than 775 adverse event reports linked to compounded GLP-1 products, many involving dangerous dosing errors. For Indian patients, the message is clear: unregulated GLP-1 copies are risky, and with affordable approved generics now available in India, there is no longer any reason to take that risk.
What Happened
On April 30, 2026, the FDA announced it is proposing to exclude semaglutide (the drug in Ozempic and Wegovy), tirzepatide (Mounjaro and Zepbound), and liraglutide from the 503B bulks list. This list determines which drugs large compounding facilities in the US are allowed to manufacture from raw bulk ingredients. During the 2023 to 2025 shortage of branded GLP-1 drugs, compounding pharmacies were temporarily allowed to make copies, and a huge gray market grew around cheap compounded injections sold through telehealth websites. The shortage is over, and the FDA is now closing that door. FDA Commissioner Marty Makary said the action reflects the agency's responsibility to protect patients and preserve the integrity of the drug approval process. Public comments are open until June 29, 2026, after which the FDA will make a final determination.
Why the FDA Is Acting
The safety record of compounded GLP-1 products has been troubling. By early 2025 the FDA had received more than 455 adverse event reports linked to compounded semaglutide and more than 320 linked to compounded tirzepatide. Many of these involved dosing errors — patients drawing the wrong amount from multidose vials and accidentally injecting five or ten times the intended dose, leading to severe vomiting, dehydration, and hospitalisation. Compounded products are not reviewed by the FDA for safety, quality, or potency before sale. Investigations also found products made with salt forms of semaglutide that were never tested in humans, and counterfeit vials with no active ingredient at all.
Why This Matters for Indian Patients
Free Consultation
Have questions about GLP-1 Therapy?
Enter your phone number — a specialist calls you back in 30 minutes. Free, no commitment.
🔒 Confidential · No spam · 10,000+ patients helped
India does not have the American 503B compounding system, but Indian patients face the same underlying danger in a different form. As GLP-1 demand has exploded in India, so have unsafe sources: imported research-grade peptide vials sold on Telegram and Instagram, gray-market compounded injections shipped from abroad, websites selling semaglutide without prescriptions, and outright counterfeit Ozempic pens. The FDA action is the strongest regulatory statement yet that unverified GLP-1 copies are a patient safety hazard — and the products reaching Indian buyers through informal channels are often even less controlled than the American compounded versions now being banned.
The irony is that Indian patients today have less reason than anyone to buy from these channels. Since the semaglutide patent expired in India in March 2026, legitimate Indian manufacturers including Sun Pharma, Cipla, and Dr. Reddy's have launched CDSCO-approved generic semaglutide at a fraction of branded prices — with monthly costs starting around Rs 1,300 to Rs 4,000 depending on dose and brand. These are properly manufactured, regulator-approved medicines available at registered pharmacies with a prescription. The price advantage that once pushed patients toward gray-market vials has largely disappeared.
How to Stay Safe
First, only take GLP-1 medication prescribed by a doctor after a proper medical assessment — these drugs are not suitable for everyone, including people with a history of certain thyroid cancers or pancreatitis. Second, buy only from registered pharmacies, and insist on sealed, labelled packaging from a known manufacturer. Third, be deeply suspicious of any seller offering injections without a prescription, vials labelled for research use, or prices that seem too good to be true. Fourth, never adjust doses yourself — the most common harm seen with compounded products was self-dosing error. If you are currently using a GLP-1 product from an unverified source, do not simply stop — speak to a doctor about switching safely to an approved version.
The Bottom Line
The world's strictest drug regulator has concluded that copies of semaglutide and tirzepatide made outside the approval system are not worth the risk. Indian patients now have safe, affordable, approved options — generic semaglutide, branded Ozempic and Wegovy, and Mounjaro — and a specialist can help you choose the right one and start treatment safely.
Free Consultation
Have questions about GLP-1 Therapy?
Enter your phone number — a specialist calls you back in 30 minutes. Free, no commitment.
🔒 Confidential · No spam · 10,000+ patients helped
Call MySurgery at 8588967050 or WhatsApp us to speak with a GLP-1 specialist. Free consultation, callback in 30 minutes.
Disclaimer: This article is based on information published on the referenced websites below and is intended for general awareness only. It is not a substitute for professional medical advice.
References: 1. US FDA — https://www.fda.gov/news-events/press-announcements/fda-proposes-exclude-semaglutide-tirzepatide-and-liraglutide-503b-bulks-list 2. Pharmacy Times — https://www.pharmacytimes.com/view/fda-moves-to-permanently-close-the-door-on-compounded-glp-1s 3. Medical News Today — https://www.medicalnewstoday.com/articles/fda-proposes-ban-bulk-compounding-semaglutide-tirzepatide
MySurgery GLP-1 Team
GLP-1 Research & Patient Education
Have questions about GLP-1 Therapy?
Free consultation. Expert doctors. Callback in 30 minutes.